Why the study?
Do human healthy and diabetic platelets exert cardioprotective effects against ischemia/reperfusion injury in isolated rat hearts?
Do human healthy and diabetic platelets exert cardioprotective effects against ischemia/reperfusion injury in isolated rat hearts?
Healthy human platelets exert cardioprotective effects against ischemia/reperfusion injury via S1P receptors and RISK pathways, but these properties are lost in platelets from patients with uncontrolled type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Healthy platelets may protect against ischemia/reperfusion injury; hypothesis-generating for diabetes-specific impairment before clinical translation.
Platelets affect myocardial damage from ischemia/reperfusion. Redox-dependent sphingosine-1-phosphate production and release are altered in diabetic platelets. Sphingosine-1-phosphate is a double-edged sword for ischemia/reperfusion injury. Therefore, we aimed to verify whether: 1) human healthy- or diabetic-platelets are cardioprotective, 2) sphingosine-1-phosphate receptors and downstream kinases play a role in platelet-induced cardioprotection, and 3) a correlation between platelet redox status and myocardial ischemia/reperfusion injury exists. Isolated rat hearts were subjected to 30-min ischemia and 1-h reperfusion. Infarct size was studied in hearts pretreated with healthy- or diabetic-platelets. Healthy-platelets were co-infused with sphingosine-1-phosphate receptor blocker, ERK-1/2 inhibitor, PI3K antagonist or PKC inhibitor to ascertain the cardioprotective mechanisms. In platelets we assessed i) aggregation response to ADP, collagen, and arachidonic-acid, ii) cyclooxygenase-1 levels, and iii) AKT and ERK-phosphorylation. Platelet sphingosine-1-phosphate production and platelet levels of reactive oxygen species (ROS) were quantified and correlated to infarct size. Infarct size was reduced by about 22% in healthy-platelets pretreated hearts only. This cardioprotective effect was abrogated by either sphingosine-1-phosphate receptors or ERK/PI3K/PKC pathway blockade. Cyclooxygenase-1 levels and aggregation indices were higher in diabetic-platelets than healthy-platelets. Diabetic-platelets released less sphingosine-1-phosphate than healthy-platelets when mechanical or chemically stimulated in vitro. Yet, ROS levels were higher in diabetic-platelets and correlated with infarct size. Cardioprotective effects of healthy-platelet depend on the platelet's capacity to activate cardiac sphingosine-1-phosphate receptors and ERK/PI3K/PKC pathways. However, diabetic-platelets release less S1P and lose cardioprotective effects. Platelet ROS levels correlate with infarct size. Whether these redox alterations are responsible for sphingosine-1-phosphate dysfunction in diabetic-platelets remains to be ascertained.
No takes yet. Share an insight, caveat, or question.
Russo et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: